NCT07680699 NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
| NCT ID | NCT07680699 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AC Camargo Cancer Center |
| Condition | Cutaneous Melanoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2025-04-23 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2025-04-23 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma. Patients are included after receiving treatment as part of routine clinical practice. Decisions about treatment, including whether to start anti-PD1 therapy before surgery, are made by the treating physician and are not influenced by the study. The study compares outcomes between patients who started anti-PD1 therapy before surgery and those treated according to the usual timing in clinical practice. No treatments are assigned as part of the study.
Eligibility Criteria
Inclusion Criteria: \- Adults (≥18 years) with histologically confirmed cutaneous melanoma stage IIB or IIC or stage III (N1c), managed in routine clinical practice. Exclusion Criteria: * Patients without sufficient clinical or follow-up data. * Patients who do not provide informed consent (for prospective cohort).
Frequently Asked Questions
Who can join the NCT07680699 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cutaneous Melanoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07680699 currently recruiting?
Yes, NCT07680699 is actively recruiting participants. Visit ClinicalTrials.gov or contact AC Camargo Cancer Center to inquire about joining.
Where is the NCT07680699 trial being conducted?
This trial is being conducted at São Paulo, Brazil.
Who is sponsoring the NCT07680699 clinical trial?
NCT07680699 is sponsored by AC Camargo Cancer Center. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.